BLUE - ブル―バ―ド・バイオ (bluebird bio Inc.) ブル―バ―ド・バイオ

 BLUEのチャート


 BLUEの企業情報

symbol BLUE
会社名 bluebird bio Inc (ブル―バ―ド・バイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ブルーバード(bluebird bio Inc.)は臨床開発段階にあるバイオテクノロジー企業であり、重症及び癌の遺伝子治療の開発に集中する。同社はレンチウイルスに基づく遺伝子治療と遺伝子編集機能を通じて、これらの分野におけるさまざまなアプリケーションを備えた統合製品プラットフォームを作成した。同社の複数の遺伝病に対する遺伝子臨床プログラムは輸血依存性β-サラセミアと重症鎌状赤血球病(SCD)を治療するLentiGlobin製品候補、脳性副腎白質ジストロフィー(CALD)を治療するLenti-D製品候補を含む。同社の腫瘍学におけるプログラムはキメラ抗原受容体(CAR) T細胞受容体(TCR)療法を含むT細胞ベースの免疫療法の開発に集中する。同社の腫瘍のリード製品候補bb2121は多発性骨髄腫の治療のためのCAR T細胞産物候補である。同社はパイプラインに応用する可能のメガTAL /ホーミングエンドヌクレアーゼ遺伝子編集技術を利用する発見研究プログラムがある。   ブル―バ―ド・バイオは、米国のバイオ医薬品企業。遺伝性疾患や難病向けに遺伝子治療製品の開発を手掛ける。主要製品候補はレンチDと呼ばれる副腎白質ジストロフィ―の治療薬と、サラセミアおよび鎌状赤血球病治療薬のレンチグロビンである。また、がん治療分野にて、がん細胞を破壊し患者自身のT細胞の遺伝子組換えなどの研究開発を手掛ける。   
本社所在地 60 Binney Street Cambridge MA 02142 USA
代表者氏名 Daniel S. Lynch ダニエルS.リンチ
代表者役職名 Independent Chairman of the Board
電話番号 +1 339-499-9300
設立年月日 33695
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 479人
url www.bluebirdbio.com
nasdaq_url https://www.nasdaq.com/symbol/blue
adr_tso
EBITDA EBITDA(百万ドル) -444.21700
終値(lastsale) 133.44
時価総額(marketcap) 7226832311.04
時価総額 時価総額(百万ドル) 7380.099
売上高 売上高(百万ドル) 35.68700
企業価値(EV) 企業価値(EV)(百万ドル) 6458.457
当期純利益 当期純利益(百万ドル) -351.15500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 bluebird bio Inc revenues increased 1% to $23.8M. Net loss increased 87% to $261.1M. Revenues reflect Collaboration revenue increase of 78% to $23M. Higher net loss reflects Change in fair value of contingent consi increase of 72% to $796K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.41 to -$5.22.

 BLUEのテクニカル分析


 BLUEのニュース

   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   bluebird bio to Present at Leerink Global Healthcare Conference  2021/02/22 21:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on
   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Investors  2021/02/22 16:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of BLUE Investors
   Insider Selling: bluebird bio, Inc. (NASDAQ:BLUE) CFO Sells $19,514.88 in Stock  2021/02/21 12:31:03 Watchlist News
bluebird bio, Inc. (NASDAQ:BLUE) CFO William D. Baird III sold 693 shares of bluebird bio stock in a transaction on Wednesday, February 17th. The stock was sold at an average price of $28.16, for a total transaction of $19,514.88. Following the completion of the sale, the chief financial officer now owns 34,081 shares of the […]
   The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings  2021/02/20 14:36:28 Benzinga
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. Bluebird bio Inc (NASDAQ: BLUE ) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS ) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease. The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates. Here are the key catalytic events for the coming week: Conferences: Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26 Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25 Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27 PDUFA Dates The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT ) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations.
   Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020  2020/12/05 17:30:00 Business Wire
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #ASH2020--BMS and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020
   Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease  2020/12/04 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patien
   bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting  2020/11/24 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3493595. To access the live webcast of blue
   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE - Stocks News Feed  2020/11/22 04:11:35 Stocks News Feed
NEW YORK, Nov. 21, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ:BLUE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether bluebird and certain of its officers and/or directors have engaged… Read More »SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. – BLUE
   Global Gene Therapy for Blood Disorders Market Assessment 2020 - Key Player such as Biomarin Therapeutics, Spark Therapeutics, Shire, bluebird bio, Inc., CRISPR Therapeutics, Medgenics, OrphageniX and many more.  2020/11/20 09:16:36 OpenPR
InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on “Global Gene Therapy for Blood Disorders Market Assessment – Revenue (US$ Mn) Forecast Till 2030” Request for Sample Pages: https://www.insightaceanalytic.com/report-details/global-gene-therapy-for-blood-disorders-market-assessment/ According to the latest research by InsightAce Analytic,
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Merrill Lynch Stick to Their Buy Rating for bluebird bio  2020/11/06 09:07:49 Investing.com
Merrill Lynch Stick to Their Buy Rating for bluebird bio
   bluebird bio Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/05 17:14:00 Stock Market Daily
bluebird bio announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Why Bluebird Bio's Stock Is Trading Lower Today  2020/11/05 16:23:16 Benzinga
Bluebird Bio (NASDAQ: BLUE ) shares are trading lower on Thursday after the company reported third-quarter earnings results. BMO also downgraded the stock from Outperform to Market Perform with a price target of $56 per share. Bluebird Bio is a clinical-stage biotechnology company that … Full story available on Benzinga.com
   Bluebird bio's stock plunges after submission delay of sickle cell disease treatment  2020/11/05 15:11:50 MarketWatch
Shares of Bluebird bio Inc. undefined traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ブル―バ―ド・バイオ BLUE bluebird bio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)